Introduction to Canagliflozin and the FDA

Canagliflozin represents a significant advancement in the management of type 2 diabetes. It belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, lowering blood glucose by blocking reabsorption of glucose in the proximal renal tubule, thereby promoting its excretion in urine. This mechanism is independent of insulin secretion, making it a valuable option for patients across a broad range of disease progression. Developed by Janssen Pharmaceuticals, it was first approved by the U.S. Food and Drug Administration (FDA) in 2013 under the brand name Invokana. Over time, its indications expanded beyond glycemic control to include reducing the risk of major adverse cardiovascular events and slowing the progression of diabetic kidney disease, establishing it as a cornerstone therapy for patients with type 2 diabetes and associated comorbidities.

The pathway from a molecule in a laboratory to a medication available at the pharmacy is among the most rigorous processes in modern medicine. The FDA approval process for canagliflozin provides a clear and instructive example of how a new therapeutic agent navigates a complex regulatory landscape. This article details each stage—from preclinical investigations through ongoing post-market surveillance—while highlighting critical milestones that ensure the drug is safe, effective, and manufactured to the highest quality standards. Healthcare professionals, researchers, and patients alike will gain a deeper appreciation for the thoroughness behind every approved medication.

The Stages of FDA Drug Approval

The FDA drug approval process is built around a systematic, phased evaluation of safety and efficacy. For canagliflozin, as with all new molecular entities, the journey unfolded in four main phases: preclinical testing, clinical trials (Phases 1 through 3), FDA review of the New Drug Application (NDA), and post-approval monitoring (Phase 4). Each phase is designed to answer specific questions about the drug’s behavior in the body, its therapeutic benefits, and any potential risks that may emerge under wider use. The process is iterative, with data from each stage informing the design of subsequent studies.

Understanding these stages illuminates why drug development typically spans 10 to 15 years and costs billions of dollars. For canagliflozin, the investment yielded not only initial approval but also a growing set of indications supported by robust outcomes trials, coupled with a safety record that compares favorably with older diabetes therapies.

Preclinical Testing

Before any human testing could begin, canagliflozin underwent extensive laboratory and animal studies. Preclinical work evaluated the drug’s pharmacological activity, pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the compound), and toxicology. Researchers used rodent and non-rodent models to identify potential adverse effects on major organ systems, reproductive function, and developing fetuses. These studies also explored the drug’s selectivity for SGLT2 over SGLT1, a related transporter in the gut, to minimize gastrointestinal side effects.

Key objectives included determining a safe starting dose for humans, understanding the drug’s mechanism at the cellular level, and ruling out unacceptable toxicity. The FDA requires that preclinical data demonstrate a favorable benefit-risk ratio before granting Investigational New Drug (IND) status. For canagliflozin, these studies confirmed its ability to lower blood glucose without causing severe hypoglycemia or off-target toxicity, paving the way for first-in-human trials. The preclinical package also included absorption, distribution, metabolism, and excretion (ADME) studies in multiple species to predict human pharmacokinetics.

It is important to note that preclinical testing does not guarantee success in humans. Many compounds fail at this stage due to toxicity, poor bioavailability, or lack of efficacy. The successful completion of these studies for canagliflozin was a significant milestone, but the most challenging and uncertain work lay ahead in the clinical phases.

Clinical Trial Phases

Clinical trials for canagliflozin were conducted in three sequential phases, each with specific goals, endpoints, and enrollment criteria. The trials involved thousands of patients across multiple countries, including those with type 2 diabetes both with and without comorbidities such as cardiovascular disease or chronic kidney disease. Trial designs incorporated randomized, double-blind, placebo-controlled, and active-comparator arms to provide rigorous comparisons. Regulatory authorities, including the FDA and European Medicines Agency, provided guidance on trial design through formal meetings and written advice.

Phase 1: Safety and Dosage

Phase 1 trials typically enroll 20 to 100 healthy volunteers or, in some cases, patients with the target condition. For canagliflozin, these early studies focused on safety, tolerability, and pharmacokinetics. Researchers administered single and multiple ascending doses to determine the maximum tolerated dose and to observe how the drug behaves in the body. Blood and urine samples were collected to measure glucose excretion, plasma concentrations, and metabolite formation. Studies also assessed the effect of food on absorption and the drug’s half-life, which supported once-daily dosing.

Phase 1 data helped establish the dosing regimen used in later trials. For canagliflozin, once-daily oral dosing proved effective and generally well tolerated. The most common side effects were mild gastrointestinal upset and increased urination—a direct consequence of its mechanism of action. No serious safety signals emerged, and the drug advanced to Phase 2 with a clear understanding of its pharmacokinetic profile across different doses.

Phase 2: Efficacy and Side Effects

Phase 2 trials involve several hundred patients and are designed to evaluate efficacy and identify the optimal dose. Canagliflozin was tested in dose-ranging studies comparing 50 mg, 100 mg, 300 mg, and placebo. The primary endpoint was reduction in glycated hemoglobin (HbA1c) after 12 to 26 weeks of treatment. Secondary endpoints included fasting plasma glucose, body weight, and systolic blood pressure. Researchers also collected pharmacokinetic data to confirm dose proportionality and to explore exposure-response relationships.

Results showed significant HbA1c reductions in a dose-dependent manner, with the 100 mg and 300 mg doses providing the best balance of efficacy and tolerability. Side effects such as genital mycotic infections and urinary tract infections emerged more frequently at higher doses but were generally manageable with appropriate monitoring and patient education. Phase 2 data also indicated potential cardiovascular benefits, including modest reductions in blood pressure and body weight, which would later be confirmed in larger outcomes trials. These findings allowed researchers to refine the Phase 3 trial design and confidently select the 100 mg and 300 mg doses for further study.

Phase 3: Confirmation in Large Populations

Phase 3 trials are the most extensive and expensive part of clinical development, enrolling thousands of patients at multiple centers worldwide. For canagliflozin, the Phase 3 program included several randomized, double-blind, placebo-controlled and active-comparator studies. The largest of these was the CANVAS (Canagliflozin Cardiovascular Assessment Study) program, which enrolled over 10,000 patients with type 2 diabetes and high cardiovascular risk. A separate, dedicated renal outcomes trial, CREDENCE, evaluated the drug’s effects on kidney disease progression in patients with diabetic kidney disease.

The primary endpoint of CANVAS was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Results demonstrated a statistically significant reduction in major adverse cardiovascular events in the canagliflozin group compared to placebo. Additionally, the drug slowed progression of albuminuria and reduced the risk of hospitalization for heart failure. The CREDENCE trial, which enrolled patients with chronic kidney disease and albuminuria, showed a 30% reduction in the risk of end-stage kidney disease, doubling of serum creatinine, or renal death.

Phase 3 also evaluated glycemic durability, safety over longer treatment periods (up to four years), and patient-reported outcomes. Common adverse events included genital infections (especially in uncircumcised men), volume depletion events (particularly in older patients taking diuretics), and rare cases of diabetic ketoacidosis in patients with reduced insulin secretion. The FDA carefully reviewed these risks during the NDA evaluation, weighing them against the substantial cardiovascular and renal benefits.

Data from all Phase 3 trials were compiled into a comprehensive New Drug Application (NDA) submitted to the FDA in early 2013. The NDA contained thousands of pages of clinical data, manufacturing specifications, proposed labeling, and a risk management plan. This submission marked the transition from drug development to regulatory review.

FDA Review and Approval

Once the NDA was submitted, the FDA began a rigorous review process that typically takes 6 to 10 months for standard applications, or 6 to 8 months for priority review. Canagliflozin was granted standard review, meaning the FDA aimed to complete its evaluation within 10 months from the submission date. The review involved multiple disciplines within the agency, each evaluating a specific aspect of the application.

NDA Submission and Content

The NDA for canagliflozin included:

  • Detailed reports from preclinical and clinical studies
  • Pharmacokinetic and pharmacodynamic data, including population PK models
  • Chemistry, manufacturing, and controls (CMC) information, including drug substance and drug product specifications
  • Proposed labeling, including prescribing information and patient Medication Guide
  • A risk evaluation and mitigation strategy (REMS) if needed
  • Clinical study reports integrated into a comprehensive summary of safety and efficacy

The FDA assembled a cross-disciplinary review team consisting of medical officers, pharmacologists, biostatisticians, chemists, and microbiologists. Each team member evaluated specific aspects of the application and prepared a written review with recommendations. The review process included a thorough assessment of data integrity, statistical analyses, and the adequacy of manufacturing controls. Inspections of clinical trial sites and manufacturing facilities were conducted to verify that data were reliable and that Good Manufacturing Practices were followed.

Advisory Committee Meeting

For many new drugs, especially those with novel mechanisms or potential safety concerns, the FDA convenes an advisory committee of external experts to provide independent advice. For canagliflozin, the Endocrinologic and Metabolic Drugs Advisory Committee met in January 2013. The committee reviewed clinical data, including the CANVAS interim analysis, which had shown a possible increase in cardiovascular events in a subgroup of patients. However, further analyses suggested that this finding was likely due to chance and not a true drug effect. The committee also discussed risks of genital infections, volume depletion, and the potential for diabetic ketoacidosis.

The committee voted 10–5 in favor of recommending approval, with conditions regarding post-market surveillance for cardiovascular safety and a requirement for dedicated renal outcomes data. This vote, while not binding, heavily influences the FDA’s final decision. The discussion highlighted the need for careful monitoring of renal function and a strong warning about ketoacidosis risk, particularly in patients with reduced insulin secretion capacity.

Following the advisory committee, the FDA conducted inspections of clinical trial sites and manufacturing facilities to ensure data integrity and compliance with Good Manufacturing Practices (GMP). These inspections are a critical part of the review process, as they verify that the data submitted in the NDA are accurate and that the drug can be consistently produced to high quality standards.

FDA Decision and Approval

On March 29, 2013, the FDA approved canagliflozin (Invokana) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The approved doses were 100 mg and 300 mg once daily. The original label included warnings about volume depletion (especially in patients with renal impairment or those taking loop diuretics), increased risk of genital infections, and a caution regarding use in patients with severe renal impairment (eGFR below 30 mL/min/1.73 m²). A boxed warning about increased risk of lower limb amputations was added later in 2016 after post-market data emerged from the CANVAS program.

Approval was contingent on the sponsor conducting post-market studies to further evaluate cardiovascular safety through the ongoing CANVAS program and to assess long-term renal outcomes in a dedicated trial (CREDENCE). The FDA also required a REMS to educate healthcare providers and patients about the risk of ketoacidosis, including atypical presentations where blood glucose may not be markedly elevated (euglycemic diabetic ketoacidosis).

Post-Approval Monitoring

FDA approval is not the end of the story. All drugs undergo ongoing surveillance through Phase 4 studies, adverse event reporting systems, and periodic safety reviews. For canagliflozin, post-market data have led to important label changes and expanded indications, demonstrating the dynamic nature of drug safety and benefit-risk assessment.

Phase 4 Studies

The CANVAS program continued as a randomized, double-blind trial that completed in 2017. Its final results confirmed the cardiovascular benefits observed in the interim analysis and led to an FDA approval of an additional indication for reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease. The CREDENCE trial, initiated as a post-market requirement, enrolled 4,401 patients with type 2 diabetes and chronic kidney disease (eGFR 30 to <90 mL/min/1.73 m² and albuminuria). Results showed a 30% reduction in the primary composite outcome of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death.

In 2018, the FDA approved canagliflozin for use in patients with type 2 diabetes and chronic kidney disease to reduce the risk of end-stage kidney disease and cardiovascular events. In 2019, the indication was further expanded to include reducing the risk of hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. These label expansions were based on high-quality evidence from large outcomes trials, underscoring the value of carefully designed post-approval studies.

Adverse Event Reporting

The FDA maintains the Adverse Event Reporting System (FAERS) to collect reports from healthcare providers, patients, and manufacturers. For canagliflozin, early post-market signals included cases of acute pancreatitis, severe hypoglycemia when used with insulin or sulfonylureas, and rare but serious cases of Fournier gangrene (necrotizing fasciitis of the perineum). In 2016, the FDA added a warning about the increased risk of leg and foot amputations based on data from the CANVAS program and other studies. The amputation risk was higher at the 300 mg dose and in patients with a prior history of amputation, peripheral vascular disease, or neuropathy.

Manufacturers are legally required to submit periodic safety update reports (PSURs) to the FDA and to conduct additional studies if the agency identifies a new safety signal. For canagliflozin, these post-market commitments have generated data that refine the drug’s risk profile and help clinicians make informed prescribing decisions. The ongoing monitoring ensures that the benefit-risk profile remains favorable as the drug is used in broader, more diverse populations than those studied in clinical trials.

Label Updates and Expanded Indications

As of 2024, canagliflozin has undergone multiple label revisions. The original 2013 approval only covered glycemic control. Subsequent indications added cardiovascular and renal benefits, making it a foundational therapy for patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The dosing has also been refined: the 100 mg dose is now recommended for patients with chronic kidney disease (eGFR 30 to 60 mL/min/1.73 m²) and for those at high risk for amputations, while 300 mg remains appropriate for patients with preserved kidney function and low amputation risk. The label now includes specific recommendations for monitoring kidney function, volume status, and signs of ketoacidosis.

External resources for the latest prescribing information include the FDA’s official drug safety page, the DailyMed label from the National Library of Medicine, and clinical trial listings on ClinicalTrials.gov.

Conclusion

The FDA approval process for canagliflozin exemplifies the rigorous, evidence-based journey from basic science to patient care. Preclinical studies laid the groundwork by demonstrating the drug’s mechanism and safety. Phase 1 through 3 clinical trials built a robust body of evidence for its efficacy in lowering blood glucose and, importantly, for its cardiovascular and renal protective effects. The FDA review ensured that the benefits of lowering blood glucose and reducing cardiovascular and renal events outweighed the risks of side effects such as genital infections, volume depletion, and amputations. Post-approval monitoring has been equally critical, revealing new indications for cardiovascular and renal protection while refining safety warnings through dedicated outcomes trials and active pharmacovigilance.

Understanding this process empowers healthcare professionals to prescribe with confidence, helps patients appreciate the safeguards that protect them, and reinforces the importance of continued surveillance even after a drug reaches the market. As the therapeutic landscape for type 2 diabetes continues to evolve with the introduction of new SGLT2 inhibitors and combination therapies, the story of canagliflozin remains a valuable case study in responsible drug development and regulatory oversight. The lessons learned from this approval process—particularly the value of large cardiovascular and renal outcomes trials—have shaped the development path for subsequent drugs in this class and have raised the bar for evidence generation in metabolic disease.

For further reading, the FDA provides detailed guidance on its approval process at Step 4: FDA Drug Review and Approval. Detailed information about the CANVAS and CREDENCE trials is available on ClinicalTrials.gov. Healthcare professionals prescribing canagliflozin should consult the current prescribing information and the FDA’s safety communications for the most up-to-date guidance.